About Octant
Octant is a synthetic biology drug discovery company that develops small-molecule therapeutics for complex diseases. Its platform combines synthetic biology, genome engineering, high-throughput chemistry, next-generation sequencing, and AI/ML to simultaneously measure the activity of thousands of receptor pathways in human cells. The company targets diseases driven by protein misfolding and mistrafficking, with programs in rare disease, oncology, and immunology.
Company details
Funding
Total raised
$115M
Last stage
Growth
Investors
Founders
Sri Kosuri
Biologist with 20+ years in synthetic biology, functional genomics, and bioinformatics. Associate Professor at UCLA in Chemistry and Biochemistry. Previously worked at the Wyss Institute and Harvard on gene synthesis, DNA information storage, and large-scale multiplexed assays.
LinkedInRamsey Homsany
Co-founder and President of Octant Bio. Also an angel investor in multiple startups.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.